Tandem Diabetes Care (Nasdaq:TNDM) announced today that it made its Mobi automated insulin delivery system available with Android devices. San Diego-based Tandem said Mobi, the world’s smallest, durable automated insulin delivery system, can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. In November, Tandem announced that it received […]
Drug-Device Combinations
Airiver Medical wins FDA breakthrough nod for drug-coated balloon, treats first patient
Airiver Medical announced today that it received FDA breakthrough device designation for its pulmonary drug-coated balloon (DCB). Additionally, Airiver announced the first treated patients in a clinical trial for the DCB. The Brooklyn Park, Minnesota-based company designed its DCB to treat central airway stenosis. Central airway stenosis (airway narrowing) can lead to prolonged intubation, tracheostomy, […]
Modular Medical prices $12M public offering to support insulin pump
Modular Medical (Nasdaq:MODD) announced the pricing of a public offering worth proceeds of approximately $12 million. San Diego-based Modular Medical’s offering includes nearly 68.1 million shares of the company’s common stock and warrants to purchase up to an aggregate of 68.1 million shares. The company priced the offering at $0.1762 per share and accompanying warrant. […]
Judge tosses class action suit accusing Abbott of sharing CGM data with Meta, Google
An Illinois judge sided with Abbott (NYSE:ABT) in a lawsuit related to alleged data sharing with its continuous glucose monitors (CGMs). In September 2024, a lawsuit filed in the Northern District of Illinois alleged that tracking tools on Abbott’s FreeStyle Libre website expose private consumer information without their knowledge or consent. The company’s FreeStyle.Abbott website […]
Kevin Sayer returns from leave of absence to chair Dexcom board
Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer notified the San Diego-based continuous glucose monitor (CGM) maker of his plan to return on Feb. 27, 2026. His return went into effect today, March 2, 2026, according to the filing. Upon his return, […]
Senseonics earns FDA IDE for next-gen Gemini CGM, posts Q4 revenue beat
Senseonics (NYSE:SENS) posted fourth-quarter results that proved mixed compared to Wall Street forecasts alongside a major pipeline announcement. Along with its fourth-quarter results, the company shared that it secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in […]
Dexcom adds Google exec to its board
Dexcom (Nasdaq:DXCM) announced that it appointed Rick Osterloh to its board of directors, effective Feb. 26, 2026. Osterloh currently serves as SVP, Platforms and Devices at Google. There, he leads a unified group spanning the tech giant’s portfolio of advanced consumer technologies. San Diego-based Dexcom said in a news release that Osterloh offers significant experience […]
Medtronic launches MiniMed Go smart MDI system with Simplera sensor in Europe
Medtronic (NYSE:MDT) announced today that it launched its MiniMed Go smart multiple daily injection (MDI) system with the Simplera sensor. The system represents the first and only solution that integrates data from the InPen smart insulin pen and the Simplera continuous glucose monitor (CGM) sensor into a single mobile app. Medtronic (soon to separate its Diabetes […]
Tandem Diabetes Care prices upsized $265M offering
Tandem Diabetes Care (Nasdaq:TNDM) today announced the pricing of a $265 million offering of convertible senior notes. San Diego-based Tandem earlier this week announced its intent to offer $200 million in notes, due 2032, in a private placement. It now says it upsized that offering by $65 million. The company also granted initial purchasers an […]
Medtronic MiniMed Diabetes IPO could reach up to $784M
In an amendment to an SEC filing, Medtronic’s (NYSE:MDT) Diabetes unit, MiniMed, today shared more details on its planned initial public offering (IPO). Medtronic announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. In that announcement, the company projected the separation within the next 18 months. It […]










